Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2019

Filing Date
Filed February 7, 2020
Period End
December 31, 2019
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 7, 2020. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (filed under this name; ticker NBIX) reported its Form 10-K for fiscal 2019.

The company describes itself as a commercial-stage biopharmaceutical company focused on neurological, endocrine and psychiatric disorders. Its primary commercial product is INGREZZA (valbenazine) for tardive dyskinesia, approved by the FDA in April 2017. Net product sales of INGREZZA were $752.9 milliona in 2019, up from $409.6 million in 2018 and $116.6 million in 2017.

Total revenues were $788.1 millionb, and the company reported net income of $37.0 million, or $0.39 per diluted share, compared with $21.1 million in 2018 and a net loss of $142.5 million in 2017. The filing highlights several pipeline catalysts. The FDA accepted an NDA for opicapone in Parkinson's disease with a PDUFA target action date of April 26, 2020, and AbbVie's NDA for elagolix in uterine fibroids with a PDUFA date in the second quarter of 2020.

Crinecerfont for congenital adrenal hyperplasia is planned for a global registration study in mid-2020. Operating expenses increased, including $154.3 millionc of acquired in-process R&D tied to the Voyager and Xenon collaborations, and SG&A rose to $354.1 million. The company held $970.2 million in cash, cash equivalents and marketable securities at December 31, 2019, and reported $152.1 million of operating cash flow for 2019.

Key risks disclosed include concentration of revenue, with two customers accounting for approximately 86% of gross product sales in 2019, and the conditional conversion feature of the $517.5 milliond 2.25% convertible senior notes due 2024, which was triggered at December 31, 2019, allowing conversion from January 2, 2020 through March 31, 2020. The notes are classified as a current liability. The company also reported an accumulated deficit of $1.1 billion and continued exposure to healthcare reform and drug pricing scrutiny.

Key Highlights

  1. INGREZZA net product sales reached $752.9 million in 2019, up from $409.6 million in 2018 and $116.6 million in 2017.
  2. Total revenues were $788.1 million in 2019, with net income of $37.0 million, or $0.39 per diluted share.
  3. Two customers accounted for approximately 86% of gross product sales in 2019 and a significant majority of accounts receivable at December 31, 2019.
  4. PDUFA target action dates in the second quarter of 2020 for opicapone (April 26, 2020) in Parkinson's disease and elagolix in uterine fibroids.
  5. Acquired in-process R&D of $154.3 million in 2019, primarily from the Voyager ($113.1 million) and Xenon ($36.2 million) collaborations.
  6. Cash, cash equivalents and marketable securities totaled $970.2 million at December 31, 2019, versus $866.9 million a year earlier.
  7. The $517.5 million 2.25% convertible senior notes due 2024 became convertible from January 2, 2020 through March 31, 2020 and are classified as a current liability.

Financial Statements

FY2019 against FY2018

Line itemFY2019FY2018Change
Revenue$788.10M$451.20M+74.7%
SG&A Expenses$354.10M$248.90M+42.3%
Operating Expenses$715.80M$414.40M+72.7%
Operating Income$72.30M$36.80M+96.5%
Interest Expense$32.00M$30.50M+4.9%
Net Income$37.00M$21.10M+75.4%
EPS (Basic)$0.40$0.23+73.9%
EPS (Diluted)$0.39$0.22+77.3%
Shares Outstanding (Basic)91.60M90.20M+1.6%
Shares Outstanding (Diluted)95.70M95.40M+0.3%

Frequently Asked Questions

  1. How much did INGREZZA sales grow and what drove 2019 profitability?

    Net product sales of INGREZZA were $752.9 million in 2019, compared with $409.6 million in 2018. The filing attributes the change in net income from 2018 to 2019 primarily to increased INGREZZA net product sales, partly offset by $154.3 million of acquired in-process R&D related to the Voyager and Xenon collaborations. Net income was $37.0 million for 2019.

  2. What are the near-term regulatory catalysts?

    The FDA accepted Neurocrine's NDA for opicapone as an adjunctive therapy in adult Parkinson's disease patients, with a PDUFA target action date of April 26, 2020. AbbVie's NDA for elagolix for heavy menstrual bleeding associated with uterine fibroids also has a PDUFA target date in the second quarter of 2020. FDA approval of opicapone would trigger a $20.0 million milestone payment from Neurocrine to BIAL.

  3. How concentrated is the company's customer base?

    All product sales are made to a limited network of specialty pharmacy providers and a specialty distributor. For 2019, the two largest customers accounted for approximately 86% of gross product sales and a significant majority of accounts receivable at December 31, 2019. The filing notes that loss of either of these customers could adversely affect revenue, results of operations and cash flows.

  4. What is the status of the convertible notes and the company's liquidity?

    The 2.25% convertible senior notes due May 15, 2024 have an aggregate principal amount of $517.5 million. The conditional conversion feature was triggered at December 31, 2019, allowing conversion from January 2, 2020 through March 31, 2020, so the notes are classified as a current liability. The company held $970.2 million in cash, cash equivalents and marketable securities at year-end and stated that its existing resources are expected to be sufficient for at least the next twelve months.